Stanford University researchers have developed a spray drying technique incorporating a glassy surfactant excipient (MoNi) to convert intravenous protein-based therapeutics into high-concentration injectable formulations compatible with standard syringes and autoinjectors. This method prevents protein aggregation and maintains stability, potentially transforming time-consuming IV infusions into simplified, rapid injections without genetic modification. Published in Science Translational Medicine, the platform offers broad applicability for biologic drug delivery.